Analyst's Rating And Market ReactionFollowing encouraging clinical trial results for NBI-1065845 in major depressive disorder, analysts maintain an Outperform rating and NBIX shares saw an uptick, reflecting the drug's promising future and contribution to the company's growth.
Clinical Trial ResultsNeurocrine announced positive top-line results from the SAVITRI study of NBI-1065845, showing significant improvement in major depressive disorder symptoms, with a favorable safety profile similar to placebo.
Drug Profile And Market PotentialNBI-1065845's novel mechanism of action and strong clinical data suggest it could be a significant new treatment option in the major depressive disorder market, with potential advantages over existing therapies.